Unum Therapeutics, Inc. IPO Research Information

Unum Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Unum Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Unum Therapeutics, Inc.	UMRX - NASDAQ	$12.00-$14.00	$12.00	$11.75	5.77 million	3/29/2018
Underwriter(s): Morgan Stanley, Cowen
Co-Manager(s): SunTrust Robinson Humphrey, Wedbush PacGrow
Industry: Health Care
Filing(s): Filed 2018-03-02 Terms Added 2018-03-19 Final Prospectus 2018-03-29

Unum Therapeutics, Inc. Quote & Chart - Click for current quote - UMRX

About Unum Therapeutics, Inc. (adapted from Unum Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "UMRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.